Sonoma Biotherapeutics
Mark joins Sonoma Biotherapeutics with over 10 years of accounting and finance experience with a demonstrated history of successfully implementing financial processes and systems.
Mark was most recently at Sangamo Therapeutics where he was responsible for various accounting and finance functions, including accounting, audit, forecasting, treasury, and accounts payable operations. Prior to Sangamo, he was at Medivation and played an integral role after the company was acquired by Pfizer. Earlier in his career, he held a role in public accounting with Deloitte.
Mark earned a BS degree in Accounting from Santa Clara University.
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.